Mohamad Makhzoumi
CIK 1630226 · last filed 2026-03-12
Mohamad Makhzoumi is a corporate insider who has filed 64 SEC Form 4 insider transactions across 23 companies since 2018. The most recent filing shows the insider bought $2.3M of KRRO on Mar 12, 2026. Across all open-market trades the lifetime net is +$215.7M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.06B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.06B
23
64
$215.69M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KRRO | 10%+ Owner | 1,297,893 | $10.50 | $13.63M | $3.30M | 2 | 2026-03-12 |
| SGP | 10%+ Owner | 5,097,538 | $21.62 | $110.21M | $15.00M | 1 | 2026-02-11 |
| NeueHealth, Inc. (BHG) Delisted | Director | 1,527,217 | $16.35 | $24.97M | $35.00M | 10 | 2025-10-06 |
| NeueHealth, Inc. (NEUE) Delisted | Director | 1,354,465 | $6.75 | $9.15M | $0 | 4 | 2025-05-15 |
| MBX | 10%+ Owner | 1,023,103 | $60.06 | $61.45M | $8.00M | 1 | 2024-09-17 |
| SVRA | 10%+ Owner | 24,471,264 | $5.33 | $130.43M | $1000.0K | 1 | 2023-07-19 |
| MIRM | 10%+ Owner | 2,186,243 | $112.23 | $245.36M | $6.75M | 2 | 2023-06-15 |
| Arcellx, Inc. (ACLX) Delisted | 10%+ Owner | 30,283 | $115.07 | $3.48M | -$5.5K | 1 | 2022-12-22 |
| Akouos, Inc. (AKUS) Delisted | 10%+ Owner | 0 | $13.29 | $0 | $10.00M | 2 | 2022-12-02 |
| IONQ.WS | 10%+ Owner | 14,616,483 | $22.45 | $328.14M | $0 | 1 | 2022-11-18 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | 10%+ Owner | 913 | $15.00 | $13.7K | $18.85M | 12 | 2022-10-21 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 0 | $0.00 | $0 | $21.03M | 4 | 2022-05-26 |
| HOOD | Director | 6,371 | $92.76 | $591.0K | -$49.2K | 5 | 2022-05-04 |
| TRVI | 10%+ Owner | 948,948 | $18.43 | $17.49M | $31.80M | 4 | 2022-04-13 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 2,563,257 | $0.49 | $1.27M | $9.51M | 2 | 2021-12-27 |
| GLUE | 10%+ Owner | 5,973,296 | $22.04 | $131.65M | $19.95M | 1 | 2021-06-30 |
| Desktop Metal, Inc. (DM) Delisted | 10%+ Owner | 208 | $4.96 | $1.0K | $0 | 1 | 2021-06-10 |
| Eargo, Inc. (EAR) Delisted | 10%+ Owner | 1,514 | $2.57 | $3.9K | $5.59M | 2 | 2021-05-26 |
| MRKR | 10%+ Owner | 1,071,428 | $1.18 | $1.26M | $10.00M | 1 | 2021-03-18 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 645,106 | $8.16 | $5.26M | $3.96M | 3 | 2020-12-07 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 2,437,689 | $4.00 | $9.75M | $4.00M | 1 | 2020-07-28 |
| NKTX | 10%+ Owner | 2,235,449 | $2.22 | $4.96M | $12.00M | 1 | 2020-07-16 |
| ARDX | 10%+ Owner | 3,482,186 | $5.08 | $17.71M | $0 | 1 | 2019-12-09 |
Recent Filings
64 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-12 | KRRO | Buy (P) | +207,100 | $2.30M | EDGAR |
| 2026-02-11 | SGP | Mixed | +7,392,301 | $15.00M | EDGAR |
| 2025-10-06 | NeueHealth, Inc. (BHG) Delisted | Mixed | −2,296,994 | $20 | EDGAR |
| 2025-05-15 | NeueHealth, Inc. (NEUE) Delisted | Exer (M) | +10,500 | $0 | EDGAR |
| 2024-10-03 | NeueHealth, Inc. (NEUE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-09-17 | MBX | Mixed | +3,614,486 | $8.00M | EDGAR |
| 2024-05-14 | NeueHealth, Inc. (NEUE) Delisted | Mixed | +4,755 | $0 | EDGAR |
| 2024-04-24 | KRRO | Buy (P) | +17,857 | $1000.0K | EDGAR |
| 2024-04-10 | NeueHealth, Inc. (NEUE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-21 | NeueHealth, Inc. (BHG) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.